🟢 Mirum Pharmaceuticals is trading 5.5% up today after RBC raised its target to $155

Mirum Pharmaceuticals is trading higher after RBC Capital raised its price target to $155 from $135, with shares at $85.85 (+5.53%) on October 9, 2026.

• RBC Capital maintained an Outperform rating; the target update was reported October 8.
• Positive Phase 3 AZURE-1 results and FDA approval of Atebrioz predate this session. Biotech is down 2.04%, which does not explain the gain; current volume information is unavailable.